Mesa Laboratories, Inc.
NASDAQ:MLABHardware, Equipment & Parts
-$0.15 today
- Market cap
- $774.56M
- Beta
- 0.93
- P/E (TTM)
- 78.3
- EPS (TTM)
- $1.21
- Dividend yield
- 0.68%
Volume 0.07M
Average 0.16M
MLAB Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Mesa Laboratories, Inc.NASDAQ: MLAB
Operating Income · Q4 FY2026 · quarter ended Mar 2026
Operating income growth accelerates
Q4 FY2026 operating income of $2.75M rose 87.1% year over year, ahead of the +13.3% change in trailing-twelve-month operating income. Sequentially, it fell 65.5% from the prior quarter. Over 3 fiscal years it compounded at +77.3% a year.
Context
- Operating income amounted to 7.4% of revenue in FY2026, up 0.7 pp from a year earlier.
- Operating income increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 1 analysts of $90.32M (+387.9%) for the fiscal year ending Mar 2027, a step up from the +13.3% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.75M-65.5% QoQ
- Last fiscal yearMar 2026
- $18.51M+13.3% YoY
- LTMMar 2026
- $18.51M+13.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +87.1% | +601.8% | +514.7 pp |
| 1 year | +13.3% | +387.9% | +374.6 pp |
| 3-year CAGR | +77.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2026
- 18.51M USD
- Year-over-year change
- +13.3%
- 4-year CAGR
- +40.9%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 18.51M | +13.3% |
| FY2025 | 2025-03-31 | 16.34M | +106.0% |
| FY2024 | 2024-03-31 | (272.08M) | -8295.0% |
| FY2023 | 2023-03-31 | 3.32M | -29.4% |
| FY2022 | 2022-03-31 | 4.7M | — |
Operating Income vs competitors
How MLAB compares with its peers on the latest reported figures
- MLAB's LTM Mar 2026 operating income of $18.51M is the 8th highest of the 11 companies compared; the peer median is $237.92M.
- Its year-over-year change of +13.3% is the 8th highest of 11, against a peer median of +17.2%.
- Operating income amounts to 7.4% of revenue for MLAB, versus a peer median of 20.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $8.52B | +5.1% | -1.7% | 18.0% | |
| LTM Jul 2026 | $1.64B | +13.5% | -2.9% | 22.2% | |
| LTM Jun 2026 | $532.09M | +13.6% | -0.7% | 25.3% | |
| LTM Jul 2026 | $358.85M | -9.8% | -23.0% | 12.3% | |
| LTM Sep 2026 | $240.84M | +119.1% | -5.5% | 19.6% | |
| LTM Jun 2026 | $235M | +5.1% | -17.6% | 9.1% | |
| LTM Jun 2026 | $96.09M | +129.8% | — | 46.0% | |
| LTM Mar 2026 | $18.51M | +13.3% | +77.3% | 7.4% | |
| LTM Sep 2026 | -$72.2M | +20.9% | — | 11.7% | |
| LTM Mar 2026 | -$78.51M | +34.0% | — | 91.0% | |
| LTM Mar 2026 | -$162.78M | +80.2% | — | 101.7% | |
| Peer median (excluding MLAB) | $237.92M | +17.2% | -4.2% | 20.9% | |
Competitors are the stored peer set for MLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 184.34M | 219.08M | 216.19M | 240.98M | 249.13M |
| Cost of Revenue | 75.25M | 85.39M | 82.94M | 90.11M | 90.86M |
| Gross Profit | 109.09M | 133.69M | 133.25M | 150.87M | 158.27M |
| Gross Margin | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% |
| Research & Development | 15.77M | 20.49M | 19.3M | 19.52M | 20.31M |
| Selling, General & Admin | 88.62M | 109.88M | 111.49M | 115.02M | 119.45M |
| Operating Expenses | 104.39M | 130.37M | 405.33M | 134.53M | 139.76M |
| Depreciation & Amortization | 25.07M | 33.13M | 31.57M | 24.53M | 23.27M |
| EBITDA | 32.53M | 37.52M | (238.38M) | 42.35M | 35.29M |
| EBITDA Margin | 17.6% | 17.1% | -110.3% | 17.6% | 14.2% |
| Operating Income | 4.7M | 3.32M | (272.08M) | 16.34M | 18.51M |
| Operating Margin | 2.6% | 1.5% | -125.9% | 6.8% | 7.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.89M | 4.77M | 5.7M | 11.86M | 10.69M |
| Other Income / Expenses | (1.13M) | (3.71M) | (3.57M) | (10.38M) | (6.5M) |
| Income Before Tax | 3.57M | (389K) | (275.65M) | 5.96M | 12.01M |
| Pre-Tax Margin | 1.9% | -0.2% | -127.5% | 2.5% | 4.8% |
| Income Tax Expense | 1.7M | (1.32M) | (21.4M) | 7.94M | 5.3M |
| Net Income | 1.87M | 930K | (254.25M) | (1.97M) | 6.71M |
| Net Margin | 1.0% | 0.4% | -117.6% | -0.8% | 2.7% |
| EPS (Basic) | 0.36 | 0.17 | (47.20) | (0.36) | 1.22 |
| EPS (Diluted) | 0.35 | 0.17 | (47.20) | (0.36) | 1.21 |
| Weighted Avg Shares | 5.21M | 5.32M | 5.39M | 5.43M | 5.51M |
| Weighted Avg Shares (Diluted) | 5.34M | 5.36M | 5.39M | 5.43M | 5.57M |
Mesa Laboratories, Inc.
NASDAQ:MLAB
Intrinsic Alpha fair value
Locked
Current Price
$137.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.